Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol Etabonate 0.25% for Rejection Prevention Post-DMEK
NCT05136443Phase 4Completed
- Sponsor
- Price Vision Group
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of loteprednol etabonate ophthalmic gel 0.38% in graft rejection, sponsored by Price Vision Group. Started Nov 2021; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
graft rejection
Beyond the preview
Go deeper on NCT05136443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136443.